กำลังโหลด
HKSEHealthcareBiotechnology
ข้อมูลล่าสุด
HK$59.20
+HK$1.15 · +1.98%
Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise, dedicated to the research and advancement of biologic medicines, with a primary focus on cancer, autoimmune conditions, and ophthalmic disorders. Its commercial portfolio encompasses several approved biologic treatments. Specifically, it markets HANLIKANG, a rituximab injection utilized for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection indicated for breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection with indications in metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. In addition to its marketed products, Shanghai Henlius is actively progressing its robust development pipeline, which includes Serplulimab, undergoing further development for applications such as squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and a range of other solid tumor types. Among its other investigational compounds are HLX04-O, a bevacizumab injection aimed at wet age-related macular degeneration; HLX22 for breast and metastatic gastric cancer; a group of therapies—HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20—collectively aimed at solid tumors; HLX11 for breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12, addressing gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14, designed to treat osteoporosis. Further expanding its pipeline, HLX26 is being developed for solid tumors and lymphoma; HLX13 is under investigation for melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71, with potential for treating COVID-19. The firm conducts its operations across Mainland China, Europe, the broader Asia-Pacific region, and various other international territories. Founded in 2010, its headquarters are situated in Shanghai, China. Shanghai Henlius Biotech, Inc. operates as a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
ข้อมูลล่าสุด
HK$59.20
+HK$1.15 · +1.98%
เวลาในวันใช้เขตเวลาHKT ข้อมูลตลาดอาจล่าช้า
Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise, dedicated to the research and advancement of biologic medicines, with a primary focus on cancer, autoimmune conditions, and ophthalmic disorders. Its commercial portfolio encompasses several approved biologic treatments. Specifically, it markets HANLIKANG, a rituximab injection utilized for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection indicated for breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection with indications in metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. In addition to its marketed products, Shanghai Henlius is actively progressing its robust development pipeline, which includes Serplulimab, undergoing further development for applications such as squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and a range of other solid tumor types. Among its other investigational compounds are HLX04-O, a bevacizumab injection aimed at wet age-related macular degeneration; HLX22 for breast and metastatic gastric cancer; a group of therapies—HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20—collectively aimed at solid tumors; HLX11 for breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12, addressing gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14, designed to treat osteoporosis. Further expanding its pipeline, HLX26 is being developed for solid tumors and lymphoma; HLX13 is under investigation for melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71, with potential for treating COVID-19. The firm conducts its operations across Mainland China, Europe, the broader Asia-Pacific region, and various other international territories. Founded in 2010, its headquarters are situated in Shanghai, China. Shanghai Henlius Biotech, Inc. operates as a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
ช่วงราคารายวัน
ปัจจุบัน HK$59.20
ช่วง 52 สัปดาห์
ปัจจุบัน HK$59.20
เวลาในวันใช้เขตเวลาHKT ข้อมูลตลาดอาจล่าช้า
Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise, dedicated to the research and advancement of biologic medicines, with a primary focus on cancer, autoimmune conditions, and ophthalmic disorders. Its commercial portfolio encompasses several approved biologic treatments. Specifically, it markets HANLIKANG, a rituximab injection utilized for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection indicated for breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection with indications in metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. In addition to its marketed products, Shanghai Henlius is actively progressing its robust development pipeline, which includes Serplulimab, undergoing further development for applications such as squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and a range of other solid tumor types. Among its other investigational compounds are HLX04-O, a bevacizumab injection aimed at wet age-related macular degeneration; HLX22 for breast and metastatic gastric cancer; a group of therapies—HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20—collectively aimed at solid tumors; HLX11 for breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12, addressing gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14, designed to treat osteoporosis. Further expanding its pipeline, HLX26 is being developed for solid tumors and lymphoma; HLX13 is under investigation for melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71, with potential for treating COVID-19. The firm conducts its operations across Mainland China, Europe, the broader Asia-Pacific region, and various other international territories. Founded in 2010, its headquarters are situated in Shanghai, China. Shanghai Henlius Biotech, Inc. operates as a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
ช่วงราคารายวัน
ปัจจุบัน HK$59.20
ช่วง 52 สัปดาห์
ปัจจุบัน HK$59.20
อัตรากำไรที่รายงานในช่วงเวลาที่มีอยู่
รายได้
รายได้จากการดำเนินงาน
รายได้สุทธิ
| รายการ (CNY) | ปีงบประมาณ 2025 | ปีงบประมาณ 2024 | ปีงบประมาณ 2023 | ปีงบประมาณ 2022 | ปีงบประมาณ 2021 |
|---|---|---|---|---|---|
| รายได้ | 6.67B CNY | 5.72B CNY | 5.39B CNY | 3.21B CNY | 1.68B CNY |
| ต้นทุนสินค้าขาย | 1.68B CNY | 1.54B CNY | 1.48B CNY | 844.62M CNY | 522.75M CNY |
| กำไรขั้นต้น | 4.98B CNY | 4.18B CNY | 3.92B CNY | 2.37B CNY | 1.16B CNY |
| การวิจัยและพัฒนา | 1.52B CNY | 1.04B CNY | 1.12B CNY | 1.39B CNY | 1.02B CNY |
| การขาย ทั่วไป และธุรการ | 2.65B CNY | 2.29B CNY | 2.14B CNY | 1.4B CNY | 800.87M CNY |
| ค่าใช้จ่ายในการดำเนินงาน | 4.17B CNY | 3.25B CNY | 3.29B CNY | 3B CNY | 1.82B CNY |
| รายได้ดอกเบี้ย | 18.3M CNY | 21.7M CNY | 8.15M CNY | 3.57M CNY | 2.69M CNY |
| ดอกเบี้ยจ่าย | 99.84M CNY | 122.89M CNY | 110.54M CNY | 105.67M CNY | 84.82M CNY |
| ค่าเสื่อมราคาและค่าตัดจำหน่าย | 346.05M CNY | 279.63M CNY | 279.63M CNY | 277.6M CNY | 200.18M CNY |
| รายได้จากการดำเนินงาน | 817.12M CNY | 939.13M CNY | 631.7M CNY | −628.53M CNY | −665.25M CNY |
| รายได้สุทธิ | 805.64M CNY | 820.47M CNY | 546.02M CNY | −695.26M CNY | −984.05M CNY |
ข้อเท็จจริงของบริษัทได้รับการปรับปรุง 6 ต.ค. 2569.
ผลประกอบการล่าสุดที่ประกาศ
ผลประกอบการล่าสุดที่ประกาศ
กองทุนซื้อขายแลกเปลี่ยนที่รายงานความเสี่ยงต่อหุ้นนี้
iShares Core MSCI Emerging Markets ETFIEMG2.49M0.00%162.19B USD0.09%US$83.44-0.17%
iShares Genomics Immunology and Healthcare ETFIDNA1.27M0.40%309.3M USD0.47%US$41.62-2.57%
State Street SPDR Portfolio Emerging Markets ETFSPEM625.57K0.00%17.46B USD0.07%US$52.905+0.16%
Dimensional - Emerging Core Equity Market ETFDFAE305.52K0.00%10.26B USD0.29%US$40.3788-0.05%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM227.85K0.00%9.77B USD0.39%US$40.815+0.04%
iShares MSCI China Small-Cap ETFECNS199.73K0.32%61.75M USD0.59%US$27.29-0.09%
Dimensional World ex U.S. Core Equity 2 ETFDFAX169.4K0.00%12.44B USD0.28%US$37.61+0.43%
State Street SPDR S&P China ETFGXC127.58K0.03%449.93M USD0.59%US$86.07-0.44%iShares Core MSCI Emerging Markets ETFIEMGiShares Genomics Immunology and Healthcare ETFIDNAState Street SPDR Portfolio Emerging Markets ETFSPEMDimensional - Emerging Core Equity Market ETFDFAEDimensional - Emerging Markets Core Equity 2 ETFDFEMiShares MSCI China Small-Cap ETFECNSDimensional World ex U.S. Core Equity 2 ETFDFAXState Street SPDR S&P China ETFGXCเนื้อหาที่สร้างโดย AI และข้อมูลตลาดที่ล่าช้ามีไว้เพื่อให้ข้อมูลและการศึกษาเท่านั้น ไม่ใช่คำแนะนำการลงทุน
